Understanding CHD9: A Potential Drug Target Or Biomarker (G80205)

Target Name: CHD9

NCBI ID: G80205

CHD9

Other Name(s): kismet homolog 2 | KIAA0308, | CHD9 variant 2 | ATP-dependent helicase CHD9 | Chromodomain helicase DNA binding protein 9, transcript variant 2 | CReMM | PPAR-alpha-interacting complex protein 320 kDa | Kismet homolog 2 | Chromodomain-helicase-DNA-binding protein 9 | ciprofibrate bound protein p240 | CHD9 variant 1 | Ciprofibrate bound protein p240 | PPAR{gamma}-interacting cofactor 320 kDa | PRIC320 | Chromodomain helicase DNA binding protein 9, transcript variant 1 | KIAA0308 | chromatin remodeling factor CHROM1 | chromatin-related mesenchymal modulator | Chromodomain-helicase-DNA-binding protein 9 (isoform 2) | Peroxisomal proliferator-activated receptor A-interacting complex 320 kDa protein | X0008 | AD013 | AD-013 | Chromatin-remodeling factor CHROM1 | Chromodomain-helicase-DNA-binding protein 9 (isoform 1) | proteinx0008 | KISH2 | Chromatin-related mesenchymal modulator | CHD9_HUMAN | CHD-9 | Chromatin remodeling factor CHROM1 | peroxisomal proliferator-activated receptor A-interacting complex 320 kDa protein | Proteinx0008 | chromodomain helicase DNA binding protein 9

Understanding CHD9: A Potential Drug Target Or Biomarker

CHD9, also known as kismet homolog 2, is a gene that has been identified in numerous scientific studies as having the potential to be a drug target or biomarker. CHD9 is a non-coding RNA molecule that has been shown to play a role in the development and progression of a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key reasons for the interest in CHD9 is its potential to intervene in the regulation of cellular processes that are involved in disease development. For example, studies have shown that CHD9 can be involved in the regulation of cell death, angiogenesis, and inflammation . Additionally, CHD9 has been shown to play a role in the regulation of gene expression, which can lead to the production of proteins that are involved in disease development.

Despite the potential implications of CHD9 as a drug target or biomarker, more research is needed to fully understand its role in disease. One of the challenges in studying CHD9 is its expression in different tissues and its effects on various cellular processes. Additionally, the functions of CHD9 in disease development may be complex and may require further study to fully understand.

In addition to its potential as a drug target or biomarker, CHD9 is also of interest to researchers because of its potential role in the development of personalized medicine. Personalized medicine involves the use of individual genetic profiles to determine the most effective treatment for an individual patient . CHD9 and its associated genetic variants have been shown to play a role in the development of personalized medicine, as they can be used to predict the response of patients to different treatments.

Another promising aspect of CHD9 is its potential to serve as a therapeutic target in neurodegenerative diseases. Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and other Pathological changes. CHD9 has been shown to be involved in the regulation of neurodegenerative diseases, and therefore, it may be a promising target for the development of new therapies for these diseases.

In conclusion, CHD9 is a gene that has the potential to be a drug target or biomarker in a variety of diseases. Its role in the regulation of cellular processes and its potential as a therapeutic target make it an attractive target for further research. As research continues to advance, it is likely that the full potential of CHD9 will be revealed and its role in disease will become increasingly understood.

Protein Name: Chromodomain Helicase DNA Binding Protein 9

Functions: Acts as a transcriptional coactivator for PPARA and possibly other nuclear receptors. Proposed to be a ATP-dependent chromatin remodeling protein. Has DNA-dependent ATPase activity and binds to A/T-rich DNA. Associates with A/T-rich regulatory regions in promoters of genes that participate in the differentiation of progenitors during osteogenesis (By similarity)

The "CHD9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHD9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets